Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2022

Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients

The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below:

(In thousands)	Three Months Ended March 31, 2022
Revenue related to deferred revenue balance at beginning of period	$	36,151
Revenue related to new performance obligations satisfied during the period		45,306
Revenue recognized under "right-to-invoice" expedient		61,114
Reimbursed travel expenses, shipping and other revenue		101
Total revenue	$	142,672

(In thousands)	Three Months Ended March 31, 2021
Revenue related to deferred revenue balance at beginning of period	$	29,401
Revenue related to new performance obligations satisfied during the period		47,263
Revenue recognized under "right-to-invoice" expedient		56,811
Reimbursed travel expenses, shipping and other revenue		177
Total revenue	$	133,652

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segments. Refer to Note 16, “Business Segments”, for further information regarding the change to our reportable segments during the first quarter of 2022.

Summary of Changes in Estimate of Credit Losses for Contract Assets

Changes in the estimate of credit losses for contract assets are presented in the table below.

	Three Months Ended March 31,
(In thousands)	2022		2021
Beginning balance	$	2,110	$	2,110
Current period provision		0		0
Ending balance	$	2,110	$	2,110
Less: Contract assets, short-term		576		576
Total contract assets, long-term	$	1,534	$	1,534

Revenue by Segment [Member]

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

	Three Months Ended March 31, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	112,271	$	6,394	$	118,665
Payer & Life Sciences		24,007		0		24,007
Total revenue	$	136,278	$	6,394	$	142,672

	Three Months Ended March 31, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	103,888	$	7,282	$	111,170
Payer & Life Sciences		22,482		0		22,482
Total revenue	$	126,370	$	7,282	$	133,652